

Dementia is one of the most pressing challenges for health and social care globally, with an estimated annual economic burden of £42 billion in the UK alone. The specific toll on individuals and their families is more difficult to quantify, yet often profound, with dementia now the most feared health condition among UK adults. The assessment of health-related quality of life in dementia has assumed increasing importance, particularly in evaluating whether the benefits of disease-modifying therapies for Alzheimer's disease newly approved in the UK justify their cost.
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet